Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MYC-dependent upregulation of the de novo serine and glycine synthesis pathway is a targetable metabolic vulnerability in group 3 medulloblastoma

6 Sept 2024

Abstract excerpt

BACKGROUND: Group 3 medulloblastoma (MBGRP3) represents around 25% of medulloblastomas and is strongly associated with c-MYC (MYC) amplification, which confers significantly worse patient survival. Although elevated MYC expression is a significant molecular feature in MBGRP3, direct targeting of MYC remains elusive, and alternative strategies are needed. The metabolic landscape of MYC-driven MBGRP3 is largely...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Cancer Research and Treatments
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39377369
DOI: 10.1093/neuonc/noae179

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MYC-dependent upregulation of the de novo serine and glycine synthesis pathway is a targetable metabolic vulnerability in group 3 medulloblastomaPMID 39377369Read ↗

Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN ‐amplified neuroblastomaSemantic proximity Read ↗

Comprehensive Metabolic Profiling of MYC-Amplified Medulloblastoma Tumors Reveals Key Dependencies on Amino Acid, Tricarboxylic Acid and Hexosamine PathwaysSemantic proximity Read ↗

Deciphering Medulloblastoma: Epigenetic and Metabolic Changes Driving Tumorigenesis and Treatment OutcomesSemantic proximity Read ↗

Understanding and imaging PHGDH-driven intrinsic resistance to mutant IDH inhibition in gliomasSemantic proximity Read ↗

Metabolic checkpoint CPS1 sustains TCA anaplerosis via urea cycle in IDH-mutant gliomas.Semantic proximity Read ↗

DCX Enhances Glioblastoma Metabolism Through Synergistic Regulation of Glutamine Synthesis and Metabolism-Related Genes for Cellular HomeostasisSemantic proximity Read ↗

Spatial pharmaco-multiomics reveals drug distribution, metabolic niches, and spatially constrained resistance in medulloblastomaSemantic proximity Read ↗

PHGDH activation fuels glioblastoma progression and radioresistance via serine synthesis pathwaySemantic proximity Read ↗

MYCN-enhanced Oxidative and Glycolytic Metabolism Reveals Vulnerabilities for Targeting NeuroblastomaSemantic proximity Read ↗

Targeting the reprogrammed metabolism in H3.3K27M pediatric high-grade gliomas.Semantic proximity Read ↗

Metabolic targeting of neuroblastoma, an updateSemantic proximity Read ↗

MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.